- Report
- October 2024
- 193 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- October 2024
- 195 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- July 2024
- 100 Pages
Global
From €5689EUR$5,950USD£4,762GBP
- Report
- April 2025
- 187 Pages
Global
From €4733EUR$4,950USD£3,962GBP
- Report
- April 2025
- 354 Pages
Global
From €5354EUR$5,600USD£4,482GBP
- Report
- April 2023
- 110 Pages
Global
From €4541EUR$4,750USD£3,802GBP
- Drug Pipelines
- July 2020
- 96 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- May 2022
- 51 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP
Ferric Carboxymaltose (FCM) is a hematological drug used to treat iron deficiency anemia. It is a form of iron replacement therapy, which is used to replenish iron stores in the body. FCM is administered intravenously and is a safe and effective treatment for iron deficiency anemia. It is also used to treat anemia caused by chronic kidney disease. FCM is a well-tolerated drug with few side effects.
FCM is a relatively new drug, but it has quickly become a popular treatment option for iron deficiency anemia. It is a cost-effective alternative to other forms of iron replacement therapy, such as oral iron supplements. FCM is also more convenient than other forms of iron replacement therapy, as it does not require frequent dosing.
FCM is available in a variety of formulations, including single-dose vials, multi-dose vials, and pre-filled syringes. It is manufactured by several companies, including Vifor Pharma, Fresenius Kabi, and Sandoz. Show Less Read more